pubmed.ncbi.nlm.nih.gov

How MHC class II molecules reach the endocytic pathway - PubMed

️Sun Jan 01 1995

How MHC class II molecules reach the endocytic pathway

P Bénaroch et al. EMBO J. 1995.

Abstract

We have examined trafficking of major histocompatibility complex (MHC) class II molecules in human B cells exposed to concanamycin B, a highly specific inhibitor of the vacuolar H(+)-ATPases required for acidification of the vacuolar system and for early to late endosomal transport. Neutralization of vacuolar compartments prevents breakdown of the invariant chain (Ii) and blocks conversion of MHC class II molecules to peptide-loaded, SDS-stable alpha beta dimers. Ii remains associated with alpha beta and this complex accumulates internally, as ascertained biochemically and by morphological methods. In concanamycin B-treated cells, a slow increase (> 20-fold) in surface expression of Ii, mostly complexed with alpha beta, is detected. This surface-disposed fraction of alpha beta Ii is nevertheless a minor population that reaches the cell surface directly, or is routed via early endosomes as intermediary stations. In inhibitor-treated cells, the bulk of newly synthesized alpha beta Ii is no longer accessible to fluid phase endocytic markers. It is concluded that the majority of alpha beta Ii is targeted directly from the trans-Golgi network to the compartment for peptide loading, bypassing the cell surface and early endosomes en route to the endocytic pathway.

PubMed Disclaimer

Cited by

The Autophagy Receptor TAX1BP1 (T6BP) improves antigen presentation by MHC-II molecules.
Sarango G, Richetta C, Pereira M, Kumari A, Ghosh M, Bertrand L, Pionneau C, Le Gall M, Grégoire S, Jeger-Madiot R, Rosoy E, Subra F, Delelis O, Faure M, Esclatine A, Graff-Dubois S, Stevanović S, Manoury B, Ramirez BC, Moris A. Sarango G, et al. EMBO Rep. 2022 Dec 6;23(12):e55470. doi: 10.15252/embr.202255470. Epub 2022 Oct 10. EMBO Rep. 2022. PMID: 36215666 Free PMC article.
CD1c molecules broadly survey the endocytic system.
Sugita M, van Der Wel N, Rogers RA, Peters PJ, Brenner MB. Sugita M, et al. Proc Natl Acad Sci U S A. 2000 Jul 18;97(15):8445-50. doi: 10.1073/pnas.150236797. Proc Natl Acad Sci U S A. 2000. PMID: 10890914 Free PMC article.
Internalization and catabolism of radiolabelled antibodies to the MHC class-II invariant chain by B-cell lymphomas.
Hansen HJ, Ong GL, Diril H, Valdez A, Roche PA, Griffiths GL, Goldenberg DM, Mattes MJ. Hansen HJ, et al. Biochem J. 1996 Nov 15;320 ( Pt 1)(Pt 1):293-300. doi: 10.1042/bj3200293. Biochem J. 1996. PMID: 8947500 Free PMC article.
Major histocompatibility complex class II compartments in human B lymphoblastoid cells are distinct from early endosomes.
Peters PJ, Raposo G, Neefjes JJ, Oorschot V, Leijendekker RL, Geuze HJ, Ploegh HL. Peters PJ, et al. J Exp Med. 1995 Aug 1;182(2):325-34. doi: 10.1084/jem.182.2.325. J Exp Med. 1995. PMID: 7629497 Free PMC article.
Competition model for upregulation of the major histocompatibility complex class II-associated invariant chain by human immunodeficiency virus type 1 Nef.
Mitchell RS, Chaudhuri R, Lindwasser OW, Tanaka KA, Lau D, Murillo R, Bonifacino JS, Guatelli JC. Mitchell RS, et al. J Virol. 2008 Aug;82(16):7758-67. doi: 10.1128/JVI.02668-07. Epub 2008 Jun 4. J Virol. 2008. PMID: 18524831 Free PMC article.

References

1. J Immunol. 1993 Jan 15;150(2):499-507 - PubMed
1. Nature. 1991 Dec 5;354(6352):392-4 - PubMed
1. J Immunol. 1980 Jul;125(1):293-9 - PubMed
1. Annu Rev Cell Biol. 1993;9:129-61 - PubMed
1. J Exp Med. 1994 Aug 1;180(2):623-9 - PubMed

How MHC class II molecules reach the endocytic pathway - PubMed